Phenotypes associated with this allele
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Supv3l1tm2.2Jkl mutation
(0 available);
any
Supv3l1 mutation
(42 available)
|
|
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Supv3l1tm2.1Jkl mutation
(0 available);
any
Supv3l1 mutation
(42 available)
Supv3l1tm2.2Jkl mutation
(0 available);
any
Supv3l1 mutation
(42 available)
Tg(KRT14-cre/ERT)20Efu mutation
(3 available)
|
|
|
Skin abnormalities in various conditional Supv3l1 mutants
adipose tissue
|
N |
• unlike in Supv3l1tm2Jkl/Supv3l1tm2Jkl floxed Tg(Mx1-cre)1Cgn mice, tamoxifen-treated mice exhibit normal growth, body composition, and weights
|
cardiovascular system
|
|
• in the ears of tamoxifen-treated mice
|
integument
|
N |
• unlike in Supv3l1tm2Jkl/Supv3l1tm2Jkl floxed Tg(Mx1-cre)1Cgn mice, tamoxifen-treated mice exhibit normal hair growth
|
|
|
• the ears of tamoxifen-treated mice exhibit chronic inflammation with marked apoptosis and focal intraepithelial lymphocyte infiltrate unlike in mice heterozygous for the floxed allele
|
|
|
• the ears of tamoxifen-treated mice
|
|
|
• the ears of tamoxifen-treated mice
|
|
|
• the ears of tamoxifen-treated mice
|
|
|
• the ears of tamoxifen-treated mice
|
|
|
• the ears of tamoxifen-treated mice are disfigured and have erythromatous swelling unlike in mice heterozygous for the floxed allele
|
|
|
• the ears of tamoxifen-treated mice
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Supv3l1tm2.1Jkl mutation
(0 available);
any
Supv3l1 mutation
(42 available)
Supv3l1tm2.2Jkl mutation
(0 available);
any
Supv3l1 mutation
(42 available)
Tg(CAG-cre/Esr1*)5Amc mutation
(9 available)
|
|
|
Thymic atrophy in Supv3l1tm2.1Jkl/Supv3l1tm2.2Jkl Tg(CAG-cre/Esr1*)5Amc/0 mice
mortality/aging
|
|
• mice die by 15 weeks of age
• tamoxifen-treated mice die by 6 weeks of age
|
immune system
|
|
• in the lungs in tamoxifen-treated mice
|
|
|
• mice exhibit thymic atrophy that develops more rapidly in tamoxifen treated mice
|
|
|
• 6-fold in tamoxifen-treated mice compared to mice heterozygous for the floxed allele
|
|
|
• tamoxifen-treated mice exhibit decreased DN2, DN3, and DN4 cells compared to mice heterozygous for the floxed allele
|
|
|
• in tamoxifen-treated mice
|
|
|
• more than 10-fold in tamoxifen-treated mice
|
|
|
• in tamoxifen-treated mice
|
|
|
• in tamoxifen-treated mice
|
|
|
• chronic and acute in untreated and tamoxifen-treated mice
|
growth/size/body
|
|
• in tamoxifen-treated mice
|
adipose tissue
|
|
• mice exhibit adipose tissue loss that develops more rapidly in tamoxifen treated mice
|
respiratory system
|
|
• chronic and acute in untreated and tamoxifen-treated mice
|
|
|
• thickened in in tamoxifen-treated mice and untreated mice
|
muscle
|
|
• mice exhibit sarcopenia atrophy that develops more rapidly in tamoxifen treated mice
|
skeleton
|
|
• mice exhibit kyphosis that develops more rapidly in tamoxifen treated mice
|
endocrine/exocrine glands
|
|
• mice exhibit thymic atrophy that develops more rapidly in tamoxifen treated mice
|
|
|
• 6-fold in tamoxifen-treated mice compared to mice heterozygous for the floxed allele
|
|
|
• in tamoxifen-treated mice, the numbers of sebaceous glands is reduced compared to in untreated mice
|
cardiovascular system
|
|
• tamoxifen-treated mice exhibit focal vascular ectasia in the skin unlike in untreated mice
• mice treated topically with tamoxifen exhibit dilated vasculature at the site of application
|
behavior/neurological
|
|
• locomotor functions fail in moribund mice
|
digestive/alimentary system
|
|
• tamoxifen-treated mice exhibit an increase in apoptosis compared to untreated mice
|
hematopoietic system
|
|
• in the lungs in tamoxifen-treated mice
|
|
|
• mice exhibit thymic atrophy that develops more rapidly in tamoxifen treated mice
|
|
|
• 6-fold in tamoxifen-treated mice compared to mice heterozygous for the floxed allele
|
|
|
• tamoxifen-treated mice exhibit decreased DN2, DN3, and DN4 cells compared to mice heterozygous for the floxed allele
|
|
|
• in tamoxifen-treated mice
|
|
|
• more than 10-fold in tamoxifen-treated mice
|
|
|
• in tamoxifen-treated mice
|
|
|
• in tamoxifen-treated mice
|
cellular
|
|
• in the lungs in tamoxifen-treated mice
|
integument
|
N |
• unlike in Supv3l1tm2Jkl/Supv3l1tm2Jkl floxed Tg(Mx1-cre)1Cgn mice, tamoxifen-treated mice exhibit normal hair growth
|
|
|
• mice exhibit adipose tissue loss that develops more rapidly in tamoxifen treated mice
|
|
|
• in tamoxifen-treated mice, the numbers of sebaceous glands is reduced compared to in untreated mice
|
|
|
• tamoxifen treated mice exhibit focal vascular ectasia, reduced adipose tissue, and atrophic muscle layer in the skin unlike in untreated mice
|
|
|
• apoptosis rates in the basal layer are increased in tamoxifen-treated mice compared to in untreated mice
|
|
|
• mild in tamoxifen-treated mice and at the site of application in mice treated topically with tamoxifen
|
|
|
• at the site of tamoxifen application when applied directly to the skin
|
|
|
• hypergranulosis develops in tamoxifen-treated mice and at the site of application in mice treated topically with tamoxifen
|
|
|
• in tamoxifen-treated mice
|
|
|
• in tamoxifen-treated mice and at the site of tamoxifen application when applied directly to the skin
|
|
|
• at the site of tamoxifen application when applied directly to the skin
|
|
|
• on the skin and tails of tamoxifen-treated mice and at the site of tamoxifen application when applied directly to the skin
|
Analysis Tools